Cargando…

Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients

Cellular immunotherapies have emerged as a successful therapeutic approach to fight a wide range of human diseases, including cancer. However, responses are limited to few patients and tumor types. An in-depth understanding of the complexity and dynamics of cellular immunotherapeutics, including wha...

Descripción completa

Detalles Bibliográficos
Autores principales: Volpe, Alessia, Adusumilli, Prasad S, Schöder, Heiko, Ponomarev, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511655/
https://www.ncbi.nlm.nih.gov/pubmed/36137649
http://dx.doi.org/10.1136/jitc-2022-004902
_version_ 1784797686026731520
author Volpe, Alessia
Adusumilli, Prasad S
Schöder, Heiko
Ponomarev, Vladimir
author_facet Volpe, Alessia
Adusumilli, Prasad S
Schöder, Heiko
Ponomarev, Vladimir
author_sort Volpe, Alessia
collection PubMed
description Cellular immunotherapies have emerged as a successful therapeutic approach to fight a wide range of human diseases, including cancer. However, responses are limited to few patients and tumor types. An in-depth understanding of the complexity and dynamics of cellular immunotherapeutics, including what is behind their success and failure in a patient, the role of other immune cell types and molecular biomarkers in determining a response, is now paramount. As the cellular immunotherapy arsenal expands, whole-body non-invasive molecular imaging can shed a light on their in vivo fate and contribute to the reliable assessment of treatment outcome and prediction of therapeutic response. In this review, we outline the non-invasive strategies that can be tailored toward the molecular imaging of cellular immunotherapies and immune-related components, with a focus on those that have been extensively tested preclinically and are currently under clinical development or have already entered the clinical trial phase. We also provide a critical appraisal on the current role and consolidation of molecular imaging into clinical practice.
format Online
Article
Text
id pubmed-9511655
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-95116552022-09-27 Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients Volpe, Alessia Adusumilli, Prasad S Schöder, Heiko Ponomarev, Vladimir J Immunother Cancer Review Cellular immunotherapies have emerged as a successful therapeutic approach to fight a wide range of human diseases, including cancer. However, responses are limited to few patients and tumor types. An in-depth understanding of the complexity and dynamics of cellular immunotherapeutics, including what is behind their success and failure in a patient, the role of other immune cell types and molecular biomarkers in determining a response, is now paramount. As the cellular immunotherapy arsenal expands, whole-body non-invasive molecular imaging can shed a light on their in vivo fate and contribute to the reliable assessment of treatment outcome and prediction of therapeutic response. In this review, we outline the non-invasive strategies that can be tailored toward the molecular imaging of cellular immunotherapies and immune-related components, with a focus on those that have been extensively tested preclinically and are currently under clinical development or have already entered the clinical trial phase. We also provide a critical appraisal on the current role and consolidation of molecular imaging into clinical practice. BMJ Publishing Group 2022-09-22 /pmc/articles/PMC9511655/ /pubmed/36137649 http://dx.doi.org/10.1136/jitc-2022-004902 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Volpe, Alessia
Adusumilli, Prasad S
Schöder, Heiko
Ponomarev, Vladimir
Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
title Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
title_full Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
title_fullStr Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
title_full_unstemmed Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
title_short Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
title_sort imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511655/
https://www.ncbi.nlm.nih.gov/pubmed/36137649
http://dx.doi.org/10.1136/jitc-2022-004902
work_keys_str_mv AT volpealessia imagingcellularimmunotherapiesandimmunecellbiomarkersfrompreclinicalstudiestopatients
AT adusumilliprasads imagingcellularimmunotherapiesandimmunecellbiomarkersfrompreclinicalstudiestopatients
AT schoderheiko imagingcellularimmunotherapiesandimmunecellbiomarkersfrompreclinicalstudiestopatients
AT ponomarevvladimir imagingcellularimmunotherapiesandimmunecellbiomarkersfrompreclinicalstudiestopatients